BOEHRINGER INGELHEIM Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BOEHRINGER INGELHEIM, and what generic alternatives to BOEHRINGER INGELHEIM drugs are available?
BOEHRINGER INGELHEIM has forty-eight approved drugs.
There are sixty-nine US patents protecting BOEHRINGER INGELHEIM drugs.
There are one thousand eight hundred and twelve patent family members on BOEHRINGER INGELHEIM drugs in sixty-three countries and two hundred and seventeen supplementary protection certificates in nineteen countries.
Summary for BOEHRINGER INGELHEIM
| International Patents: | 1812 |
| US Patents: | 69 |
| Tradenames: | 37 |
| Ingredients: | 29 |
| NDAs: | 48 |
| Patent Litigation for BOEHRINGER INGELHEIM: | See patent lawsuits for BOEHRINGER INGELHEIM |
| PTAB Cases with BOEHRINGER INGELHEIM as petitioner: | See PTAB cases with BOEHRINGER INGELHEIM as petitioner |
Drugs and US Patents for BOEHRINGER INGELHEIM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-002 | Jul 12, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-001 | Jul 12, 2013 | RX | Yes | No | 10,004,743*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin | TABLET;ORAL | 206073-002 | Jan 30, 2015 | RX | Yes | Yes | 8,883,805*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614-004 | Jan 27, 2020 | RX | Yes | Yes | 9,415,016 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-003 | Jul 12, 2013 | RX | Yes | Yes | 9,539,258*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BOEHRINGER INGELHEIM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | 6,739,333 | ⤷ Sign Up |
| Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin | TABLET;ORAL | 206073-001 | Jan 30, 2015 | 8,178,541 | ⤷ Sign Up |
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-002 | Jul 12, 2013 | 6,251,912 | ⤷ Sign Up |
| Boehringer Ingelheim | STRIVERDI RESPIMAT | olodaterol hydrochloride | SPRAY, METERED;INHALATION | 203108-001 | Jul 31, 2014 | 6,988,496 | ⤷ Sign Up |
| Boehringer Ingelheim | SPIRIVA | tiotropium bromide | POWDER;INHALATION | 021395-001 | Jan 30, 2004 | RE38912*PED | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 400 mg | ➤ Subscribe | 2013-06-21 |
| ➤ Subscribe | Tablets | 10 mg/5 mg and 25 mg/5 mg | ➤ Subscribe | 2018-08-01 |
| ➤ Subscribe | Tablets | 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg | ➤ Subscribe | 2015-05-04 |
| ➤ Subscribe | Tablets | 80 mg/12.5 mg and 40 mg/12.5 mg | ➤ Subscribe | 2008-12-31 |
| ➤ Subscribe | Extended-release Capsules | 25 mg and 200 mg | ➤ Subscribe | 2007-02-01 |
| ➤ Subscribe | Tablets | 0.125 mg, 0.5 mg, 1 mg and 1.5 mg | ➤ Subscribe | 2005-06-24 |
| ➤ Subscribe | Capsules | eq. to 75 mg base and 150 mg base | ➤ Subscribe | 2014-10-20 |
| ➤ Subscribe | Tablets | 0.75 mg | ➤ Subscribe | 2008-07-31 |
| ➤ Subscribe | Inhalation Powder Capsules | 18 mcg | ➤ Subscribe | 2018-05-11 |
| ➤ Subscribe | Tablets | 5 mg/500 mg5 mg/1000 mg12.5 mg/500 mg12.5 mg/1000 mg | ➤ Subscribe | 2018-08-01 |
| ➤ Subscribe | Extended-release Tablets | 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg | ➤ Subscribe | 2010-06-01 |
| ➤ Subscribe | Extended-release Tablets | 5 mg/1000 mg10 mg/1000 mg12.5 mg/1000 mg25 mg/1000 mg | ➤ Subscribe | 2018-08-01 |
| ➤ Subscribe | Tablets | 20 mg, 30 mg and 40 mg | ➤ Subscribe | 2017-07-12 |
| ➤ Subscribe | Tablets | 10 mg and 25 mg | ➤ Subscribe | 2018-08-01 |
| ➤ Subscribe | Tablets | 20 mg, 40 mg and 80 mg | ➤ Subscribe | 2006-12-26 |
| ➤ Subscribe | Tablets | 80 mg/25 mg | ➤ Subscribe | 2009-02-27 |
| ➤ Subscribe | Capsules | 100 mg and 150 mg | ➤ Subscribe | 2018-10-15 |
| ➤ Subscribe | Tablets | 0.25 mg | ➤ Subscribe | 2005-05-27 |
| ➤ Subscribe | Capsules | eq. to 110 mg base | ➤ Subscribe | 2015-12-15 |
| ➤ Subscribe | Oral Suspension | 7.5 mg/5 mL | ➤ Subscribe | 2009-12-17 |
| ➤ Subscribe | Extended-releaseTablets | 2.5 mg/1000 mg 5 mg/1000 mg | ➤ Subscribe | 2018-03-28 |
| ➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2015-05-04 |
| ➤ Subscribe | Extended-release Tablets | 2.25 mg and 3.75 mg | ➤ Subscribe | 2011-07-26 |
International Patents for BOEHRINGER INGELHEIM Drugs
Supplementary Protection Certificates for BOEHRINGER INGELHEIM Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1532149 | PA2011013,C1532149 | Lithuania | ⤷ Sign Up | PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001, 2011-08-24 EU/1/11/707/002, 2011-08-24 EU/1/11/707/003, 2011-08-24 EU/1/11/707/004, 2011-08-24 EU/1/11/707/005, 2011-08-24 EU/1/11/707/006, 2011-08-24 EU/1/11/707/007, 2011-08-24 EU/1/11/707/008, 2011-08-24 EU/1/11/707/00 2011082 |
| 1532149 | 92128 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE |
| 1084705 | SPC/GB14/084 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LINAGLIPTIN; REGISTERED: UK EU/1/11/707/001-011 20110830 |
| 1224170 | 17/2015 | Austria | ⤷ Sign Up | PRODUCT NAME: NINTEDANIB UND DESSEN PHYSIOLOGISCH VERTRAEGLICHE SALZE, INSBESONDERE NINTEDANIB ESILAT; REGISTRATION NO/DATE: EU/1/14/954 (MITTEILUNG) 20141125 |
| 1532149 | CA 2013 00001 | Denmark | ⤷ Sign Up | PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION ENANTIOMERER OG SALTE DERAF - SAERLIGT LINAGLIPTIN - I KOMBINATION MED METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/12/780/001-028 20120720 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
